Evidence map›Paper›PMID 32957804›Full record

ArticleClinical trials (London, England)2020

Summarising salient information on historical controls: A structured assessment of validity and comparability across studies.

Anthony Hatswell, Nick Freemantle, Gianluca Baio, Emmanuel Lesaffre, Joost van Rosmalen

Registry-linked trialAbstract read
In one paragraph

Article in Clinical trials (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07337161 (Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07337161 narecruitingnot on this mapstarted 2025, after this paper: background citation

Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma

TypeinterventionalSponsorDavid PalmaRan2025 to 2035Enrolled90ConditionsCutaneous, Head and Neck Cancer Squamous Cell CarcinomaArmsSBRT, Standard Radiation
3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anthony HatswellDepartment of Statistical Science, University College London, London, UK.ORCID 0000-0003-1129-326X
Nick FreemantleInstitute of Clinical Trials and Methodology, University College London, London, UK.
Gianluca BaioDepartment of Statistical Science, University College London, London, UK.
Emmanuel LesaffreL-Biostat, KU Leuven, Leuven, Belgium.
Joost van RosmalenDepartment of Biostatistics, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0002-9187-244X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile placebo-controlled randomised controlled trials remain the standard way to evaluate drugs for efficacy, historical data are used extensively across the development cycle. This ranges from supplementing contemporary data to increase the power of trials to cross-trial comparisons in estimating comparative efficacy. In many cases, these approaches are performed without in-depth review of the context of data, which may lead to bias and incorrect conclusions.

methodsWe discuss the original 'Pocock' criteria for the use of historical data and how the use of historical data has evolved over time. Based on these factors and personal experience, we created a series of questions that may be asked of historical data, prior to their use. Based on the answers to these questions, various statistical approaches are recommended. The strategy is illustrated with a case study in colorectal cancer.

resultsA number of areas need to be considered with historical data, which we split into three categories: outcome measurement, study/patient characteristics (including setting and inclusion/exclusion criteria), and disease process/intervention effects. Each of these areas may introduce issues if not appropriately handled, while some may preclude the use of historical data entirely. We present a tool (in the form of a table) for highlighting any such issues. Application of the tool to a colorectal cancer data set demonstrates under what conditions historical data could be used and what the limitations of such an analysis would be.

conclusionHistorical data can be a powerful tool to augment or compare with contemporary trial data, though caution is required. We present some of the issues that may be considered when involving historical data and what (if any) statistical approaches may account for differences between studies. We recommend that, where historical data are to be used in analyses, potential differences between studies are addressed explicitly.

Indexed as

BiasColonic NeoplasmsData Interpretation, StatisticalHumansOutcome Assessment, Health CarePatient SelectionRandomized Controlled Trials as TopicResearch DesignHistorical controlmatching-adjusted indirect comparisonpower priorpropensity scoring

Identifiers

PMID32957804
PMCPMC7649932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.